Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Online business Stages for Little Retailers - 2See the metal guts of a satellite in this wild X-ray view | Space photo of the day for Dec. 4, 2025
- 3The most exciting exoplanet discoveries of 2025
- 4Foot fossil discovery could reshape human evolutionary history
- 5Vote in favor of Your Number one kind of pie
- Figure out How to Get the Most Familiar Drive for Seniors in SUVs
- Figure out How to Pick a Crematorium: Key Contemplations.
- Favored Chinese Dish: Make Your Determination
- Figure out How to Forestall Tooth Staining
- Procter & Gamble changes Crest toothpaste packaging to address Texas AG fluoride concerns
- Why the weirdest sea level changes on Earth are happening off the coast of Japan
- Most loved Fish Dish: What's Your Sea Pleasure?
- There are thousands of aligned holes in Peru. Archaeologists now think they know who made them
- Must-See Attractions in Australia
